Gubra — April 2026
-
MedWatch 16/4 "Gubra har droppet udviklingen af hypet søvnmiddel: Professor peger på prisen" & "På trods af stor interesse for orexin-baserede lægemidler blandt verdens medicinalgiganter har Gubra for nylig droppet sit udviklingsprogram, der ifølge selskabet havde ”enormt potentiale”." https://medwatch.dk/brancher/Medicinal___Biotek/article19197747.ece
-
Gubra-partner tager vægttabskandidat til fase 2 https://proinvestor.com/investornyt/1437319/gubra-partner-tager-vaegttabskandidat-til-fase-2
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind